Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 17, Number 6—June 2011

CME ACTIVITY - Research

Cefepime-Resistant Pseudomonas aeruginosa

Ehimare Akhabue, Marie Synnestvedt, Mark G. Weiner, Warren B. Bilker, and Ebbing LautenbachComments to Author 
Author affiliations: Author affiliation: University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA

Main Article

Table 2

Multivariable model of risk factors for cefepime-resistant Pseudomonas aeruginosa infection, Philadelphia, PA, USA, 2001–2006*

Variable Unadjusted OR Adjusted OR (95% CI) p value
Prior use of extended-spectrum cephalosporin 2.87 2.18 (1.57–3.04) <0.001
Prior use of extended-spectrum penicillin 2.99 1.91 (1.22–2.99) 0.005
Prior use of quinolone 2.61 1.96 (1.38–2.78) <0.001
Prior use of carbapenem 2.74 1.70 (0.90–3.21) 0.10
Transfer from outside facility 1.85 1.49 (1.09–2.04) 0.01
Length of hospital stay before culture NA 1.00 (0.99–1.01)† 0.81

*OR, odds ratio; CI, confidence interval; NA, not applicable. No substantive changes were found when above analyses were limited to bloodstream isolates only.
†Odds associated with each 1-day increase in hospital stay.

Main Article

TOP